Kesmalea Therapeutics Appoints Robert Johnson as CEO To Lead Development of New Class of Oral, CNS Penetrant Protein Degraders
Johnson is co-founder of Boston-based Affinia Therapeutics and former CEO of UK biopharma Adrestia Therapeutics Kesmalea’s SELFTAC® platform is designed to solve the ‘size problem’ of large, bifunctional protein degraders by transforming them into small molecules SELFTAC® drug candidates will combine oral dosing and CNS penetration with powerful protein degradation and a rational design process […]
